Favorable News Coverage Somewhat Unlikely to Impact OncoGenex Pharmaceuticals (ACHV) Share Price
Press coverage about OncoGenex Pharmaceuticals (NASDAQ:ACHV) has been trending positive on Tuesday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news impact score of 0.29 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.8335539537955 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, ValuEngine raised OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th.
OncoGenex Pharmaceuticals (ACHV) opened at 3.09 on Tuesday. OncoGenex Pharmaceuticals has a 1-year low of $2.76 and a 1-year high of $10.29. The company has a 50-day moving average price of $1.15 and a 200 day moving average price of $0.62. The stock’s market capitalization is $8.45 million.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/favorable-news-coverage-somewhat-unlikely-to-impact-oncogenex-pharmaceuticals-achv-share-price/1490186.html.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.